Effectiveness of Topical Steroid Therapy for Prevention of Regorafenib associated Hand-foot Skin Reaction

Abstract

Introduction: Hand-foot Skin Reaction (HFSR) often hinders completion of Regorafenib therapy. No established prophylaxis exists against multikinase inhibitor-associated HFSR and further improvement of prophylaxis for HFSR is needed. Therefore, we offer multiagent therapy to prevent Regorafenib-associated HFSR comprising topical steroid (0.05% difluprednate) ointment and 20% urea-based cream.